BroadOak Capital Partners advised Omixon on its sale of the company to Werfen. Omixon, a privately held company based in Budapest, Hungary, develops and commercializes NGS technology for transplant diagnostics.
The full press release is below.
October 16, 2024 (Barcelona, Spain): Werfen announced today that it has completed the acquisition of Omixon after obtaining all necessary regulatory and antitrust approvals.
Omixon is a privately held company based in Budapest, Hungary, focused on the development and commercialization of Next Generation Sequencing (NGS) technologies in transplant diagnostics. The acquisition expands Werfen’s portfolio of transplant diagnostics solutions for hospitals and clinical laboratories.
“We are very excited to welcome our new colleagues from Omixon to our Transplant business line. With the transaction now complete, we start a new chapter to continue delivering innovative solutions in transplant diagnostics”, said Carlos Pascual, CEO, Werfen.
Attila Bérces, founder and CEO of Omixon added “I am proud of Omixon’s innovative products and achievements in transplant diagnostics. Joining Werfen marks an exciting new chapter, enabling us to expand our global reach and enhance our innovative solutions. Together, we will better serve the transplant community worldwide.”
The purchase price was approximately US$25 million and was funded with cash on hand.
Stay connected
Partner with BroadOak